Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus

被引:3
|
作者
Schmeusser, Benjamin N. [1 ]
Midenberg, Eric [2 ]
Palacios, Arnold R. [3 ]
Ali, Adil A. [1 ]
Patil, Dattatraya H. [1 ]
Higgins, Michelle [1 ,4 ,5 ]
Nabavizadeh, Reza [1 ]
Croll, Benjamin [1 ]
Williams, Milton [6 ]
Sheehy, John [1 ]
Zheng, Bill [1 ]
Narayan, Vikram M. [1 ]
Joshi, Shreyas S. [1 ]
Ogan, Kenneth [1 ]
Psutka, Sarah P. [7 ,8 ]
Bilen, Mehmet A. [9 ]
Master, Viraj A. [1 ,10 ]
机构
[1] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
[2] Univ Louisville, Sch Med, Dept Urol, Louisville, KY USA
[3] Creighton Univ, Sch Med, Dept Urol, Omaha, NE USA
[4] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA
[6] Univ Alabama Birmingham, Dept Urol, Birmingham, AL USA
[7] Univ Washington, Dept Urol, Seattle, WA USA
[8] Fred Hutchinson Canc Ctr, Seattle, WA USA
[9] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[10] Emory Univ, Dept Urol, 1365 Clifton Rd NE,Bldg B,Suite 1400, Atlanta, GA 30322 USA
关键词
Inferior vena cava; Kidney cancer; Nephrectomy; Sarcopenia; Body composition; RADICAL NEPHRECTOMY; VENA-CAVA; SURGICAL-MANAGEMENT; BODY-COMPOSITION; SOLID TUMORS; COMPLICATIONS; SARCOPENIA; OBESITY; CANCER; MASS;
D O I
10.1016/j.clgc.2023.04.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low muscle mass, defined as sarcopenia, is a risk factor for worse outcomes in malignancy, including renal cell carcinoma. This study evaluates the association of low muscle mass with mortality and complications in patients with renal cell carcinoma with venous tumor thrombus. Preoperative sarcopenia was associated with worse overall and cancer specific survival. Background: Renal cell carcinoma (RCC) with tumor thrombosis often requires nephrectomy and tumor thrombectomy. As an extensive and potentially morbid operation, patient preoperative functional reserve and body composition is an important consideration. Sarcopenia is a risk factor for increased postoperative complications, systemic therapy toxicity, and death solid organ tumors, including RCC. The influence of sarcopenia in RCC patients with tumor thrombus is not well defined. This study evaluates the prognostic ability of sarcopenia regarding surgical outcomes and complications in patients undergoing surgery for RCC with tumor thrombus. Methods: We retrospectively analyzed patients with nonmetastatic RCC and tumor thrombus undergoing radical nephrectomy and tumor thrombectomy. Skeletal muscle index (SMI; cm 2 /m 2 ) was measured on preoperative CT/MRI. Sarcopenia was defined using body mass index- and sex-stratified thresholds optimally fit via a receiver-operating characteristic analysis for survival. Associations between preoperative sarcopenia and overall (OS), cancer-specific survival (CSS), and 90-day major complications were determined using multivariable analysis. Results: 115 patients were analyzed, with median (IQR) age and body mass index of 69 (56-72) and 28.6 kg/m 2 (23.6-32.9), respectively. 96 (83.4%) of the cohort had ccRCC. Sarcopenia was associated with shorter median OS ( P = .0017) and CSS ( P = .0019) in Kaplan-Meier analysis. In multivariable analysis, preoperative sarcopenia was prognostic of shorter OS (HR = 3.38, 95% confidence interval [CI] 1.61-7.09) and CSS (HR = 5.15, 95% CI 1.46-18.18). Notably, 1 unit increases in SMI were associated with improved OS (HR = 0.97, 95% CI 0.94-0.999) but not CSS (HR = 0.95, 95% CI 0.90-1.01). No significant relationship between preoperative sarcopenia and 90-day major surgical complications was observed in this cohort (HR = 2.04, 95% CI 0.65-6.42). Conclusion: Preoperative sarcopenia was associated with decreased OS and CSS in patients surgically managed for nonmetastatic RCC and VTT, however, was not predictive of 90-day major postoperative complications. Body composition analysis has prognostic utility for patients with nonmetastatic RCC and venous tumor thrombus undergoing surgery.
引用
收藏
页码:475 / +
页数:12
相关论文
共 50 条
  • [1] BLAND THROMBUS AS AN INDEPENDENT RISK FACTOR FOR SURVIVAL IMPLICATIONS IN RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS
    Liu, Zhuo
    Zhang, Li
    Li, Liwei
    Zhang, Hongxian
    Tang, Shiying
    Zhao, Xun
    Wang, Guoliang
    Tian, Xiaojun
    Zhang, Shudong
    Wang, Shumin
    Ma, Lulin
    JOURNAL OF UROLOGY, 2020, 203 : E859 - E861
  • [2] Venous tumor thrombus consistency: is it a prognostic factor of survival for patients with renal cell carcinoma?
    Jia, Zhuo
    Tang, Lu
    Liu, Kan
    Guo, Aitao
    Huang, Qingbo
    Peng, Cheng
    Ding, Xiaohui
    Zhang, Lifeng
    Liu, Guojun
    Yang, Guoqiang
    Wang, Baojun
    Li, Hongzhao
    Zhang, Xu
    Ma, Xin
    UPDATES IN SURGERY, 2023, 75 (07) : 2033 - 2038
  • [3] Venous tumor thrombus consistency: is it a prognostic factor of survival for patients with renal cell carcinoma?
    Zhuo Jia
    Lu Tang
    Kan Liu
    Aitao Guo
    Qingbo Huang
    Cheng Peng
    Xiaohui Ding
    Lifeng Zhang
    Guojun Liu
    Guoqiang Yang
    Baojun Wang
    Hongzhao Li
    Xu Zhang
    Xin Ma
    Updates in Surgery, 2023, 75 : 2033 - 2038
  • [4] Low Lymphocyte-to-Monocyte Ratio Is the Potential Indicator of Worse Overall Survival in Patients with Renal Cell Carcinoma and Venous Tumor Thrombus
    Zapala, Lukasz
    Kunc, Michal
    Sharma, Sumit
    Biernat, Wojciech
    Radziszewski, Piotr
    DIAGNOSTICS, 2021, 11 (11)
  • [5] The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus
    Hutchinson, Ryan
    Rew, Charles
    Chen, Gong
    Woldu, Solomon
    Krabbe, Laura-Maria
    Meissner, Matthew
    Sheth, Kunj
    Singla, Nirmish
    Shakir, Nabeel
    Master, Viraj A.
    Karam, Jose A.
    Matin, Surena F.
    Borregales, Leonardo D.
    Wood, Christopher
    Masterson, Timothy
    Thompson, R. Houston
    Boorjian, Stephen A.
    Leibovich, Bradley C.
    Abel, E. Jason
    Bagrodia, Aditya
    Margulis, Vitaly
    UROLOGY, 2018, 115 : 119 - 124
  • [6] Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
    Master, Viraj A.
    Schmeusser, Benjamin N.
    Osunkoya, Adeboye O.
    Palacios, Arnold R.
    Midenberg, Eric
    Yantorni, Lauren
    Ogan, Kenneth
    Bilen, Mehmet A.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 50 - 55
  • [7] The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus
    Ihaddadene, R.
    Yokom, D. W.
    Le Gal, G.
    Moretto, P.
    Canil, C. M.
    Delluc, A.
    Reaume, N.
    Carrier, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (06) : 855 - 859
  • [8] Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
    Gu, Liangyou
    Li, Hongzhao
    Chen, Luyao
    Li, Xintao
    Wang, Baojun
    Huang, Qingbo
    Zhang, Fan
    Fan, Yang
    Gao, Yu
    Peng, Cheng
    Ma, Xin
    Zhang, Xu
    TRANSLATIONAL ONCOLOGY, 2017, 10 (06): : 949 - 955
  • [9] Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus
    Whitson, Jared M.
    Reese, Adam C.
    Meng, Maxwell V.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (02) : 259 - 263
  • [10] Preoperative Gamma-Glutamyltransferase Is Associated with Cancer-Specific Survival and Recurrence-Free Survival of Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus
    Luo, Cheng
    xu, Ben
    Fan, Yu
    Yu, Wei
    Zhang, Qian
    Jin, Jie
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017